Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 46.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 55,101 shares of the biotechnology company's stock after selling 47,872 shares during the period. Summit Partners Public Asset Management LLC owned approximately 0.09% of Ascendis Pharma A/S worth $8,227,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC boosted its position in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after buying an additional 80 shares during the period. Searle & CO. purchased a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $205,000. Rhumbline Advisers grew its position in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Pursue Wealth Partners LLC purchased a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $217,000. Finally, Algert Global LLC lifted its position in shares of Ascendis Pharma A/S by 54.6% during the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company's stock worth $297,000 after purchasing an additional 770 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND traded down $0.24 during mid-day trading on Friday, hitting $136.08. The company had a trading volume of 491,960 shares, compared to its average volume of 451,948. Ascendis Pharma A/S has a 12 month low of $97.86 and a 12 month high of $161.00. The stock has a market cap of $8.25 billion, a price-to-earnings ratio of -16.87 and a beta of 0.66. The firm's 50 day simple moving average is $132.21 and its two-hundred day simple moving average is $132.24.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Equities analysts forecast that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of recent analyst reports. Oppenheimer lowered their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a report on Friday, November 15th. Wells Fargo & Company lifted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Finally, Evercore ISI boosted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $191.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.